Pharmacogenomics – pro
Pharamcogenomics promises to decrease in: (1) the number of adverse drug reactions; (2) the number of failed drug trials; (3) the time it takes to get a drug approved; (4) the length of time patients are on medication; (5) the number of medications patients must take to find an effective therapy; (6) the effects of a disease on the body (through early detection). However, as stated by TPA MSSS et al, this science is still in its infancy and is E?I for routine clinical use.
Van Driest SL, Shi Y, Bowton EA, et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 2014; 95(4):423431.
Yuan, J. et. al. Preemptive Pharmacogenomic Testing for Precision Medicine. J Mol Diag. 2016; 18(3): 438-445.
T P A, M SS, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. J Clin Med Res. 2009 Oct;1(4):191-4.